Literature DB >> 22672259

Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.

Robert Hoerster, Philipp Muether, Claudia Dahlke, Katrin Mehler, André Oberthür, Bernd Kirchhof, Sascha Fauser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22672259     DOI： 10.1111/j.1755-3768.2012.02469.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  32 in total

1.  Estrogen therapy to treat retinopathy in newborn mice.

Authors:  Wenjing Shi; L I Zhu; Yuhuan Wang; Baoyang Hu; Honglei Xiao; Guoming Zhou; Chao Chen
Journal:  Exp Ther Med       Date:  2015-06-05       Impact factor: 2.447

2.  Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.

Authors:  Andreas Stahl; Tim U Krohne; Nicole Eter; Isabel Oberacher-Velten; Rainer Guthoff; Synke Meltendorf; Oliver Ehrt; Sabine Aisenbrey; Johann Roider; Heinrich Gerding; Claudia Jandeck; Lois E H Smith; Johanna M Walz
Journal:  JAMA Pediatr       Date:  2018-03-01       Impact factor: 16.193

3.  Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.

Authors:  Christopher K Hwang; G Baker Hubbard; Amy K Hutchinson; Scott R Lambert
Journal:  Ophthalmology       Date:  2015-02-14       Impact factor: 12.079

4.  Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.

Authors:  Ying Zhou; Yanrong Jiang; Yujing Bai; Jing Wen; Li Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-09       Impact factor: 3.117

Review 5.  Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Clin Perinatol       Date:  2014-09-23       Impact factor: 3.430

Review 6.  Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.

Authors:  Nita G Valikodath; Michael F Chiang; R V Paul Chan
Journal:  Curr Opin Ophthalmol       Date:  2021-09-01       Impact factor: 4.299

7.  Experimental histopathological study on retinal and renal cellular response to intravitreous antiangiogenic drugs.

Authors:  João Borges Fortes Filho; Mauricio Maia; Marcia Beatriz Tartarella; Fabíola Schons Meyer; Bárbara Gastal Borges Fortes; Lúcia Maria Kliemann
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

8.  [Current therapeutic options in retinopathy of prematurity].

Authors:  T U Krohne; S Aisenbrey; F G Holz
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

9.  [Pathogenesis of retinopathy of prematurity].

Authors:  A Stahl; W A Lagrèze; H T Agostini
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

10.  Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments.

Authors:  Jie Peng; Tingyi Liang; Chunli Chen; Qi Zhang; Yu Xu; Jingjing Liu; Peiquan Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-11       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.